Ultimovacs is developing novel immunotherapies against cancer. Lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed by c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.
More Ultimovacs content >Investment summary
Ultimovacs is a biotechnology company focused on developing a next generation cancer vaccine with virtually universal potential. Lead asset, UV1, activates the immune system to recognise cancer cells that express human telomerase reverse transcriptase (hTERT, or telomerase), which is present in over 85% of all cancer types. For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments. Ultimovacs’ R&D strategy is to combine UV1 with checkpoint inhibitors due to an expected treatment synergy. The broad R&D programme includes four Phase II trials in different solid tumours, which will enrol more than 500 patients in total. Readouts are expected over 2022/2023, all within cash reach. In May 2021, the first results from a Phase I trial of UV1 in advanced melanoma in combination with Keytruda showed an impressive ORR.
Y/E Dec |
Revenue (NOKm) |
EBITDA (NOKm) |
PBT (NOKm) |
EPS (öre) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2019A | 0.0 | (64.2) | (61.2) | (267.0) | N/A | N/A |
| 2020A | 0.0 | (121.4) | (120.6) | (398.0) | N/A | N/A |
| 2021E | 0.0 | (153.7) | (152.5) | (477.0) | N/A | N/A |
| 2022E | 0.0 | (159.9) | (159.0) | (497.0) | N/A | N/A |
Industry outlook
Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.
Last updated on 03/08/2021Content on Ultimovacs
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (NOKm) | 299.6 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Carlos de Sousa | CEO |
| Hans Vassgård Eid | CFO |
| Gustav Gaudernack | CSO |
| Jens Bjørheim | CMO |
| Ton Berkien | CBO |